Deferasirox vs deferiprone (DFO)
- Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 195 participantsVery low
It is very uncertain whether summary of findings: Comparison 4 ‐ deferasirox (DFX) film‐coated… changes incidence of SAEs compared with DFX dispersible tablets (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings: Comparison 3 ‐ deferiprone (DFP) changes total SAEs compared with deferasirox (DFX) (very low certainty).
Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).
It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).
The review found no eligible studies for this question.